OncoMatch/Clinical Trials/NCT05692635
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Is NCT05692635 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Gadolinium for brain metastases.
Treatment: Gadolinium — The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIA, IIIB, IIIC
Performance status
ECOG 0–3(Limited self-care)
Lab requirements
Kidney function
egfr > 30 ml/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05692635 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IIIA or IIIB or IIIC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages